![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 294, Issue 1, 313-322, July 2000
Department of Pediatrics, Baylor College of Medicine, Houston, Texas
| |
Abstract |
|---|
|
|
|---|
We reported earlier that 3-methylcholanthrene (MC) persistently induces hepatic ethoxyresorufin O-deethylase activities (CYP1A1) in rats for up to 45 days. In this investigation, we tested the hypotheses that persistent expression of CYP1A1 activities is paralleled by sustained induction of CYP1A1/CYP1A2 apoproteins and their mRNAs and that this phenomenon is mediated by mechanisms other than retention of MC in the rat. Rats were given MC (93 µmol/kg) i.p., once daily for 4 days, and CYP1A1/1A2 parameters were measured in liver at selected time points. MC-elicited increases in CYP1A1/1A2 activities, apoprotein contents, and mRNA levels were sustained for several weeks after the last dose of MC treatment. MC also caused long-term induction of CYP1A1 in lungs and mammary glands. Rats treated with [3H]MC once daily for 4 days excreted 92.3% of the administered radioactivity in feces and urine by day 15. The intrahepatic concentration of MC at the 15-day time point was 270 pmol/g. Dose-response studies showed that administration of MC (2 µmol/kg), which produced an intrahepatic concentration of 271 pmol/g after 24 h, did not induce CYP1A1/1A2 activities, strongly suggesting that the sustained induction of CYP1A1/1A2 was not due to retention of the parent MC in the body. Electrophoretic mobility shift assays revealed that persistent CYP1A1 induction by MC involved Ah receptor-independent mechanisms. In conclusion, our results support the hypothesis that persistent expression of CYP1A1/1A2 by MC is mediated by mechanisms independent of the retention of the parent carcinogen.
| |
Introduction |
|---|
|
|
|---|
3-Methylcholanthrene
(MC) is one of the most potent polycyclic aromatic hydrocarbon
(PAH) carcinogens known (Harvey, 1982
). Exposure of rodents to MC
causes tumors of many organs, including the lung (Rasmussen et al.,
1984
) and mammary gland (Huggins et al., 1961
). MC is an inert molecule
by itself, but metabolism of MC by CYP enzymes leads to the formation
of chemically reactive intermediates that are capable of binding
covalently to DNA, a critical step in the initiation of carcinogenesis
(Guengerich, 1988
).
The CYP enzymes are a multigene family of hemoproteins of the
microsomal mixed function oxidase system that is central to the
activation and detoxication of carcinogens and other toxic chemicals
and to the metabolism of a wide array of endogenous substances and
xenobiotics, including drugs, pesticides, and organic pollutants
(Guengerich, 1990
). The CYP1A family comprises two proteins, CYP1A1 and
1A2, that play important roles in carcinogen activation (Guengerich,
1988
). Recent studies have shown CYP1B1, a newly discovered enzyme,
also to be active in PAH-mediated carcinogenesis (Bowes et al., 1996
).
The hepatic CYP1A1/1A2 enzymes are inducible by the hepatocarcinogen
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Whitlock, 1987
),
by PAHs such as MC (Thomas et al., 1983
) and benzo[a]pyrene (BP) (Conney, 1986
), and by cigarette smoke
in humans (Kawajiri et al., 1991
). Moreover, MC induces CYP1A1 in extrahepatic tissues such as lung (Nebert and Gelboin, 1969
) and mammary tissues (Christou et al., 1995
), which are target organs for
MC-mediated carcinogenesis (Huggins et al., 1961
; Rasmussen et al.,
1984
). A recent study has suggested that, in addition to its well
established role of metabolism of polycyclic aromatic hydrocarbons and
environmental pollutants, MC-inducible CYP1A1 may also participate in
one or more critical life processes, such as cell division, migration,
and apoptosis (Dey et al., 1999
).
The mechanisms of induction of CYP1A1/1A2 by MC or TCDD have been
investigated extensively (Safe, 1995
; Denison and Phelan, 1998
). The
inducer, on entry into the cell, interacts with the Ah receptor (AHR),
which is a cytosolic protein. The inducer-receptor complex is
translocated into the nucleus, where it binds to the Ah receptor
nuclear translocator (ARNT), and this complex in turn interacts with
specific regulatory elements, termed Ah receptor elements (AhREs), 5'
to the CYP1A1/1A2 and phase II enzyme [e.g., glutathione
S-transferase-
, NADP(H) quinone reductase] genes, resulting in enhanced expression of the CYP1A1, CYP1A2, and phase II
enzymes encoded by the Ah locus (Safe, 1995
; Denison and
Phelan, 1998
). In addition to the AhREs, several negative regulatory
elements are located on the CYP1A1 promoter (Boucher et al.,
1995
).
The events occurring during the process of induction have been studied
extensively, but relatively little is known regarding the return of
drug-metabolizing enzymes to preinduction activities after cessation of
xenobiotic exposure. In animals exposed to persistent chemicals such as
TCDD (Gasiewicz et al., 1986
), induction of CYP1A1 and phase II enzymes
persists for several weeks after cessation of TCDD administration and
is attributed to the long biological half-life of TCDD (Gasiewicz et
al., 1986
). Beebe et al. (1992)
have demonstrated a prolonged induction
of CYP1A1 enzyme in lungs of mice exposed to a single dose of Aroclor
1254, which correlates with retention of several polychlorinated
biphenyls in tissues.
When induced by phenobarbital (Li et al., 1992
) or
-napthoflavone
(Moorthy et al., 1994
), the CYP enzymes return to normal within 5 days
after withdrawal of treatment. In rats, a single dose of MC (20-25
mg/kg) induces aryl hydrocarbon hydroxylase (AHH) activity (Poland and
Glover, 1974
) and CYP1A1 mRNA level (Bresnick et al., 1981
)
after 24 h, followed by return of enzyme activity and mRNA levels
within 5 to 7 days. However, Boobis et al. (1977)
showed that a single
dose of MC (80 mg/kg) increases total CYP contents and AHH activities
in mice for up to 9 days. Masaki et al. (1984)
reported increased total
hepatic CYP contents in rats up to 8 days after multiple
administrations of MC, and DePierre et al. (1982)
showed induction of
total hepatic CYP contents that persists for 2 to 3 weeks. However,
mechanisms by which MC elicits sustained CYP1A1 induction have not been reported.
In this study, we investigated the mechanisms of sustained induction of CYP1A1 by MC. To this end, we tested the hypotheses that sustained induction of CYP1A enzymes in liver by MC is accompanied by up-regulation of CYP1A1/1A2 apoproteins and their mRNAs and that this phenomenon is mediated by mechanisms other than those due to long-term retention of the carcinogen in the body.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals
MC, calcium chloride, Tris, sucrose, NADP+, ethoxyresorufin, glucose 6-phosphate, and glucose-6-phosphate dehydrogenase were purchased from Sigma Chemical Co. (St. Louis, MO). Methoxyresorufin was purchased from Molecular Probes (Eugene, OR). Ring-labeled [3H]MC (radiochemical purity >99.9%) was obtained from ChemSyn Laboratories (Lawrence, KS). Polyvinylidene difluoride membranes and buffer components for electrophoresis and Western blotting were obtained from Bio-Rad Laboratories (Hercules, CA). The primary monoclonal antibody to CYP1A1 was a gift from Dr. P. E. Thomas (Rutgers University, New Brunswick, NJ). Goat anti-mouse IgG conjugated with horseradish peroxidase (HRP) was from Bio-Rad Laboratories. CYP1A1 cDNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA were gifts from Dr. Frank Gonzalez of the National Cancer Institute (Bethesda, MD) and Dr. T. Tamura of our department, respectively.
Animals
Two-month-old female Sprague-Dawley rats (180-200 g) were obtained from Harlan Sprague-Dawley (Houston, TX). The animals were acclimatized for 7 days before the start of the experiment and randomized into three groups of 6 to 10 animals each. Tap water and food (Purina Rodent Lab Chow 5001; Purina Mills, Richmond, IN) were available ad libitum. A 12-h light/dark cycle was maintained.
Animal Treatment
Female Sprague-Dawley rats were treated with MC (93 µmol/kg)
in corn oil (CO) (2 ml/kg), or were given equal volumes of CO i.p.,
once daily for 4 days. At selected time points, animals were
sacrificed, and microsomes were isolated immediately from portions of
liver, lung, and mammary tissues, and stored at
80°C until
analysis. The remainder of the livers were stored at
80°C for later
isolation of RNA. Some CO- or MC-treated animal livers were used for
isolation of nuclei. For dose-response studies, animals were
administered [3H]MC (0-100 µmol/kg, 100 µCi/kg) and sacrificed 24 h after dosing. The livers were
analyzed for CYP1A1/1A2 induction and levels of parent MC.
Preparation of Microsomes
The livers were excised, weighed, and homogenized in 10 mM
Tris-HCl, pH 7.4, containing 0.25 M sucrose; microsomes were prepared by the calcium chloride precipitation method (Cinti et al., 1972
). Microsomes from lungs and mammary glands were prepared by differential centrifugation (Matsubara et al., 1974
). Lungs were perfused with cold
saline before excision and subsequent preparation of microsomes. Protein concentrations were estimated by the Bradford dye-binding method (Bradford, 1976
).
Isolation of Nuclei
Nuclei and nuclear protein extracts from livers of CO- or
MC-treated animals were prepared according to the procedure of Okino et
al. (1992)
. The nuclear protein extracts were stored at
80°C until use.
Enzyme Assays
Total CYP contents and EROD and methoxyresorufin
O-demethylase (MROD) activities in microsomes were assayed
essentially as described previously (Moorthy et al., 1993
, 2000
).
Electrophoresis and Western Blotting
Liver microsomes (30 µg of protein) were subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) in 7.5%
acrylamide gels, followed by Western blotting, as reported in a recent
paper from our laboratory (Moorthy et al., 2000
). Detection of
CYP1A1/1A2 proteins on the Western blots was accomplished by the use of
a monoclonal antibody to CYP1A1 that cross-reacts with CYP1A2 as the
primary antibody and goat anti-mouse IgG conjugated with HRP as the
secondary antibody (Moorthy et al., 2000
). The blots were developed
with the HRP color reagent 4-chloro-1-naphthol (Moorthy et al., 2000
).
Northern Hybridization
Total liver RNA was isolated using a modification of the
procedure of Chomczynski and Sacchi (1987)
. The RNA (20 µg/sample) was loaded onto a 1% agarose/formaldehyde denaturing gel, separated by
electrophoresis, and transferred to nitrocellulose filters. The filters
containing separated RNA were prehybridized by exposure to 20 mM
Na2HPO4, pH 7.6, 10×
Denhardt's reagent, 100 µg/ml heat-denatured salmon sperm DNA, and
7% SDS for approximately 3 h at 55°C. After prehybridization,
the solutions were discarded, and nitrocellulose filters were
hybridized at 55°C for 16 h by using the same solution used for
prehybridization and adding 10% dextran and the
32P-labeled CYP1A1 cDNA probe (20 × 106 cpm) that was prepared by the random prime
technique (Hamburg et al., 1994
). The hybridized filters were washed
three times for 20 min with 3× sodium chloride sodium citrate (SSC)
(1× SSC, 0.15 M sodium chloride, 0.015 M sodium citrate), and 1% SDS
at 68°C to decrease nonspecific binding of radioactive transcripts to
the filter. After these washes, the membranes were exposed to
autoradiography. Relative levels of CYP1A1/1A2 mRNAs were quantitated by phosphorimager analysis. GAPDH cDNA probe was used as an RNA transfer and loading control. For this, the nitrocellulose membranes were stripped and hybridized with GAPDH cDNA probe, followed by exposure to autoradiography.
Uptake, Distribution, and Excretion of [3H]MC
Uptake of [3H]MC into Liver. A single dose of [3H]MC (372 µmol/kg) (specific activity, 0.86 mCi/mmol) was administered i.p. to female Sprague-Dawley rats. The animals were sacrificed at selected time points, from 4 to 24 h after treatment. The livers were dissected and homogenized, and aliquots corresponding to 100 mg of liver were solubilized in Soluene 350, mixed with 15 ml of Hionic Fluor, and counted for radioactivity using a Packard liquid scintillation counter. Quenching corrections were calculated from quench curves generated by the machine. Soluene 350, Hionic Fluor, and the scintillation counter were purchased from Packard Instrument Company (Meriden, CT).
Disappearance of [3H]MC-Derived Radioactivity from Liver and i.p. Fat. Twelve animals were administered [3H]MC (93 µmol/kg; specific activity, 0.86 mCi/mmol) i.p., once daily for 4 days. Three animals from each group were sacrificed at 1, 8, or 15 days after the last treatment. Hepatic levels of [3H]MC were determined as described above. For determination of levels of [3H]MC in i.p. fat, fatty tissues were removed from the mesenchymal, epididymal, and mesenteric tissues and homogenized in 10 mM PBS, pH 7.4; 100-mg portions were processed for measurements of radioactivity.
Estimation of Intrahepatic Concentrations of Parent [3H]MC. The liver tissues of [3H]MC-exposed animals were homogenized in 10 mM Tris-HCl buffer, pH 7.4, and extracted three times with 2 volumes of ethyl acetate. The ethyl acetate fractions were combined, concentrated, and chromatographed on Eastman Kodak silica gel thin-layer plates with fluorescent indicator. The solvent system was hexane:ethyl acetate, 9:1. A small amount of unlabeled MC (1-2 µg) was spotted alongside the biological samples containing [3H]MC and its metabolites to locate on the chromatogram, under UV light, the parent [3H]MC. The Rf of MC was 0.67. The chromatogram was cut into several rectangular zones, and the amount of radioactivity in each zone was measured in a scintillation counter. The radioactivity in the zone corresponding to Rf of 0.67, which represented the parent [3H]MC, was used to estimate the amount of parent [3H]MC in liver.
Excretion of [3H]MC from Rats. Animals were housed in metabolic cages for collection of feces and urine. The animals were given [3H]MC (93 µmol/kg; specific activity, 0.86 mCi/mmol) once daily for 4 days. Urine and feces were collected daily for up to 15 days after cessation of MC treatment. The feces were homogenized in water, aliquots were heated in Soluene 350 for 4 to 6 h at 68°C, and evels of radioactivity were determined by liquid scintillation counting Radioactivity in urine was measured by mixing a 100-µl aliquot with 15 ml of Hionic Fluor, followed by counting of radioactivity.
Concentration of [3H]MC Remaining in Body Organs and Carcasses. Concentrations of [3H]MC and its metabolites remaining 15 days after cessation of MC treatment were estimated by dissection of all major organs, followed by processing of the tissues for radioactivity measurements, as described for liver. The remaining carcasses were dehydrated by heating in a vacuum oven and ground using a mortar and pestle; the resulting powder was analyzed for radioactivity. The results are expressed as percentage of dose, to reflect whole organ distribution, and per gram of tissue, to reflect the relative concentrations of the chemical.
Electrophoretic Mobility Shift Assays (EMSA)
EMSAs were performed as described by Okino et al. (1992)
.
Briefly, the nuclear proteins (15 µg) were preincubated with
poly(dI-dC) (2.5 µg) on ice for 10 min, followed by incubation at
room temperature for 20 min with 75,000 cpm of
-32P-labeled double-stranded oligonucleotides
that contain the AhREs (Pendurthi et al., 1993
) in the presence of EMSA
buffer (25 mM HEPES, 1 mM EDTA, 1 mM DTT, 10% glycerol, 500 mM KCl, pH
7.5). In some experiments, the nuclear extracts were incubated with a
50-fold excess of cold AhRE-specific oligonucleotide, before the
addition of the
-32P-labeled probe. The
labeled samples were separated by nondenaturing PAGE (4% gels) at 200 V for 2 h. The gel was dried, and radioactivity was located by
autoradiography using Kodak X-ray film.
Statistical Analysis
Data obtained from individual animals are expressed as means ± S.E. Statistical analysis was performed by ANOVA. Two-way ANOVA was performed to determine the effect of MC on EROD or MROD activities at selected time points, with MC and time as the two dependent variables. Statistical significance between control and treated groups for each time point was assessed by modified t tests, with P < .05 being considered significant. One-way ANOVA was performed to determine the effect of MC on CYP1A1 or CYP1A2 mRNA levels. Statistical significance between different groups was assessed by Tukey's post hoc test, with P < .05 being considered significant.
| |
Results |
|---|
|
|
|---|
Resorufin Ether O-Dealkylase Activities
On the 1st day after four daily doses of MC, treated rats showed
hepatic EROD activities that were 48 times the activities observed in
animals treated with vehicle not containing MC (Fig. 1). The EROD activities remained higher
than vehicle-treated controls through day 28 (Fig. 1). Two-way ANOVA
revealed a significant effect on EROD activities of MC treatment and
time and a significant interaction between the two factors. MC also
induced MROD activities. At the 1-day time point, MC induced MROD
activities by 12-fold over controls (Fig. 1), and this induction
persisted for up to 15 days (Fig. 1). Similar to EROD data, ANOVA
showed a significant effect on MROD activities of treatment with MC and
time, as well as a significant interaction between the two factors. The
sustained elevation of EROD and MROD activities was noticed also in
animals given a single dose (372 µmol/kg) of MC (data not shown).
|
CYP1A1/1A2 Apoproteins
As seen in Fig. 2, induction of both
CYP1A1 and 1A2 proteins was observable by Western analysis for up to 45 days in MC-treated rats. CYP1A2, but not CYP1A1, was readily detectable
in control liver. Densitometric analysis (data not shown) indicated
that the CYP1A1 protein levels were 95 and 90% of the 1-day value at 8 and 15 days, respectively. By days 28 and 45, the protein levels declined to 30 and 15% of the 1-day value, respectively. CYP1A2 protein induction was also sustained at extents similar to those observed for CYP1A1 (data not shown).
|
CYP1A1/1A2 mRNA Levels
To determine whether the sustained induction of CYP1A1/1A2 enzyme
activities and apoprotein contents was accompanied by corresponding increases in mRNA levels, we performed Northern hybridization analysis
on total RNA from livers isolated from control and MC-exposed animals
with cDNA probes for CYP1A1, which cross-hybridizes with CYP1A2 mRNA.
As shown in Fig. 3, at the 1-day time
point, MC samples displayed a significant induction of the CYP1A1 (23S)
and CYP1A2 (18S) mRNAs, respectively. Notably, a clear hybridization
band was obtained at 18S with normal liver RNA. Quantitation of mRNA levels by a phosphorimaging technique revealed that MC induced CYP1A1
and 1A2 mRNAs by 25.4- and 4.4-fold, respectively, over the
corresponding controls (Fig. 4). At the
15-day time point, MC-treated animals continued to display elevated
mRNA levels, with CYP1A1 and 1A2 levels being 16- and 3-fold,
respectively, over controls.
|
|
Persistent Induction of CYP1A1 in Extrahepatic Tissues
The effect of MC on EROD activities in lung at selected time
points is shown in Fig. 5. Comparison of
EROD activities between MC-exposed and control animals revealed a
55-fold induction of EROD by MC at 1 day (Fig. 5). On day 15, the MC
samples continued to display induction of EROD activities, being
56-fold greater than the corresponding controls. In mammary tissues,
comparison of EROD activities between MC-treated and control animals
indicated 7-fold greater activities in MC samples versus controls at 1 day (Fig. 6). At the 15-day time point,
the EROD activities in the animals exposed to MC were 3.8-fold higher
than controls.
|
|
Uptake, Distribution, and Excretion of [3H]MC
Uptake of [3H]MC by Liver.
The uptake of
[3H]MC by the liver after i.p. administration
of a single dose of [3H]MC is presented in Fig.
7. After a small lag, a rapid and linear increase in the concentration of MC in liver was observed. By 24 h, the level of MC and its metabolites corresponded to 1.5% of the
administered MC dose.
|
Disappearance of [3H]MC from Liver.
To determine
the rate of disappearance of [3H]MC from liver
under conditions used to study sustained induction of CYP1A1/1A2 by MC,
we studied the profile of total radioactivity in liver after four i.p.
doses of [3H]MC. One day after the last
treatment, only 0.94% of radioactivity was recovered in liver (Fig.
8), in contrast with the 1.5% noticed after a single dose of MC (372 µmol/kg) (Fig. 7), suggesting that MC
stimulated its own metabolism. At 8 days, the radioactivity fell to
0.3% of the total dose, and by 15 days, the total radioactivity represented 0.09% of the administered dose (Fig. 8). The measured radioactivity represents free MC, its metabolites, and metabolites bound to cellular macromolecules. To estimate the intrahepatic concentration of parent MC at the 15-day time point, the liver tissues
were extracted with ethyl acetate, and the ethyl acetate extract was
chromatographed by thin-layer chromatography. As shown in Table
1, the intrahepatic concentration of
parent MC, 15 days after cessation of MC treatment, was 270 pmol/g.
|
|
Disappearance of Radioactivity from i.p. Fat.
As shown in Fig.
9, the radioactivity from i.p. fat also
disappeared rapidly, as evidenced by the concentration of MC and its
metabolites dropping from 1.03% of the administered dose at the 1-day
time point to 0.11% at the 15-day time point (Fig. 9).
|
Excretion of [3H]MC from Rats.
Although the
above-mentioned data suggested extensive metabolism of MC in liver, the
possibility of sequestration of MC into different storage sites (e.g.,
fatty tissues) was not totally excluded. Therefore, we performed
experiments to determine the excretion rate of MC from rats. Animals
housed in metabolic cages were administered
[3H]MC as described under Materials and
Methods. Urine and feces were collected daily for up to 15 days
after cessation of MC treatment. The total recovery was 93%. Of the 93 µmol of MC administered, approximately 50 µmol of MC and its
derivatives were recovered in feces and urine during the 4-day
treatment period. This represented 54% of the given dose (data not
shown). On the 1st day after MC withdrawal, 10 µmol of MC and its
metabolites were present in the feces. By day 2, more than 68% of the
administered dose had been excreted (Fig.
10). By day 15, more than 92.3% of
[3H]MC had been excreted, with feces being the
major route of excretion of radioactivity (Fig. 10).
|
|
Dose-Response Studies.
As shown in Table
3, a dose-dependent induction of EROD and
MROD activities was noticed 24 h after a single dose of MC. No significant induction of total CYP contents or EROD/MROD activities was
seen at doses of MC ranging from 0 to 2 µmol/kg. The mean intrahepatic concentration of parent MC, 24 h after administration of MC (2 µmol/kg), was 271 pmol/g (Table 3). Administration of MC (5 µmol/kg), which produced an intrahepatic MC concentration of 525 pmol/g after 24 h, led to 1.5-, 8.9-, and 3.1-fold induction of
hepatic CYP contents, EROD and MROD activities, respectively (Table 3).
Treatment of animals with doses of MC greater than 5 µmol/kg led to
greater increases of total CYP contents and EROD and MROD activities,
reaching the maximum level of induction at a dose of 50 µmol/kg,
which produced an intrahepatic MC concentration of 1850 pmol/g.
|
Nuclear MC-AhR Complexes In Vivo
Specific binding of the AHR to AhREs can be determined by EMSA
(Okino et al. 1992
). To determine whether sustained induction of
hepatic CYP1A1/1A2 by MC is dependent on the interaction of ligand-activated AhR in the nucleus with AhREs on the CYP1A1 promoter, we performed EMSAs using the nuclear protein extracts from CO- (Fig.
11, lane 1) and MC- (Fig. 11, lanes
2-4) treated animals. As shown in lane 2, a nuclear protein that binds
to the AHREs was identified in livers of rats 24 h after
termination of treatment with MC (93 µmol/kg), which was administered
i.p., once daily for 4 days. The shifted band was competed off in the
presence of 50-fold excess of AhRE-specific oligonucleotide (lane 4).
This protein was not observed in rats treated with CO (lane 1) or in animals 15 days after termination MC treatment (lane 3).
|
| |
Discussion |
|---|
|
|
|---|
In this study, we investigated the mechanisms of long-term
induction of CYP1A1/1A2 by MC in rats. The dramatic increase in EROD
and MROD activities at the 1-day time point in livers of animals
exposed to MC indicated induction of CYP1A1 and 1A2 enzymes, on the
basis of evidence that EROD and MROD activities are relatively specific
for CYP1A1 and 1A2, respectively (Moorthy et al., 2000
). Our data (Fig.
1) showing statistically significant increases in EROD and MROD
activities for several weeks after cessation of MC treatment suggested
that MC elicited a prolonged induction of CYP1A1/1A2 enzymes (Fig. 1).
The fact that sustained induction of the enzyme activities was paralleled by persistent induction of the apoproteins for CYP1A1 and 1A2 (Fig. 2) supports the idea that the phenomenon of persistent induction of CYP1A1/1A2 activities was a result of long-term induction of their corresponding apoproteins. Because our Northern hybridization experiments showed sustained up-regulation of CYP1A1/1A2 mRNA levels after treatment with MC (Figs. 3 and 4), it is unlikely that MC caused persistent induction of CYP1A1/1A2 primarily by inhibiting the degradation of the corresponding apoproteins, although this mechanism may have, in part, contributed to the sustained CYP1A1 induction by MC. The sustained increase in the levels of mRNAs for CYP1A1 and 1A2 by MC was presumably due to enhanced rates of transcription of the corresponding genes. The possible contribution of message stabilization to the persistent augmentation of CYP1A1/1A2 mRNA levels has not been excluded, and it is possible that post-transcriptional mechanisms may have also contributed to the sustained induction.
The observation that MC elicited sustained induction of EROD (CYP1A1)
activities in extrahepatic tissues such as the lungs (Fig. 5) and
mammary glands (Fig. 6) suggested that this phenomenon is of relevance
to carcinogenesis because lungs and mammary glands are target organs
for the carcinogenesis mediated by MC and other PAHs (Huggins et al.,
1961
; Rasmussen et al., 1984
). The findings of Beebe et al. (1992)
demonstrating a correlation between persistent induction of CYP1A1
enzyme in the lungs of mice exposed to the tumor promoter Aroclor 1254 indicate the significance of sustained CYP1A1 induction to
tumorigenesis. We had earlier reported that MC did not elicit sustained
induction in kidney, a nontarget organ for PAH-mediated carcinogenesis
(Li et al., 1992
), suggesting that the prolonged induction in lung and
mammary gland may have implications for carcinogenesis.
We reported earlier (Moorthy et al., 1994
) that the environmentally
prevalent compound dibenz[ac]anthracene (DBA) also elicits a long-term induction of CYP1A1/1A2 in rat liver. On the other hand, BP
and naphthacene do not elicit a prolonged induction (Moorthy et al.,
1994
). Because both MC and DBA possess a benz[a]anthracene bay region, we hypothesized that a benz[a]anthracene bay
region may be an important structural requirement in mediating the
sustained response. If PAHs can elicit sustained induction of CYP1A1 in lungs and/or mammary tissues of humans, it is possible that this phenomenon may contribute to human cancers of the lung and/or breast.
Our data pertaining to the uptake, distribution, and elimination of
[3H]MC in vivo (Figs. 7-10, Tables 1 and 2)
revealed rapid metabolism and clearance of the carcinogen from the rat.
As shown in Fig. 8, only 0.94% of the administered dose was recovered
in liver 1 day after termination of MC treatment, suggesting that MC
was metabolized and eliminated quickly from liver. The observation that, of a total recovery of 93%, greater than 92.3% of radioactivity was recovered in feces and urine (Fig. 10) suggests that MC was almost
entirely excreted from the body and was not sequestered into different
storage sites of the body. The fact that the bulk of the excreted
radioactivity (~97%) was associated with the feces (Fig. 10) was
consistent with extensive hepatic metabolism of MC, followed by biliary
excretion and elimination via the feces (Daniel et al., 1967
). The
observation that little radioactivity (~3%) was excreted in the
urine over the 15-day time period (Fig. 10) excluded the possibility
that in vivo tritium exchange of [3H]MC with
water may have resulted in underestimation of the levels of MC that
persisted in the body. Overall, the results were consistent with the
experiments of Bresnick et al. (1967)
who recovered only 0.5% of the
dose in liver 14 h after a single dose of MC. Furthermore, Levine
and Singer (1972)
have shown that i.v. administration of MC leads to
swift metabolism and elimination of the carcinogen. Other PAHs such as
BP and 7,12-dimethyl benz[a]anthracene are also eliminated
rapidly from rats (Daniel et al., 1967
).
The residual concentrations of MC and its derivatives in our studies were approximately 0.09 µmol in whole liver and 0.45 µmol in the whole body at the 15-day time point (Fig. 8). The concentration of parent MC in liver at this time point was 270 pmol/g (Table 1). The fact that administration of a single dose of MC (2 µmol/kg), which produced an intrahepatic concentration of 271 pmol/g after 24 h, did not cause a significant induction of CYP1A1/1A2 (Table 3) strongly suggests that the sustained induction of CYP1A1/1A2 by MC is mediated by mechanisms other than persistence in the liver of the parent carcinogen. Furthermore, the observation that an intrahepatic MC concentration of 1850 pmol/g, produced 24 h after the administration of a single i.p. dose of MC (50 µmol/kg), was required to elicit a 32-fold induction of hepatic EROD activities (Table 3) lends credence to the hypothesis that the 37-fold elevation of EROD activities noticed 15 days after cessation of MC treatment (Fig. 1), when the intrahepatic MC concentration was 270 pmol/g, was not due to the persistence of the parent carcinogen in liver. This was in contrast to chemicals such as TCDD and polychlorinated biphenyls, which elicit prolonged induction CYP enzymes due to retention of the chemicals in body tissues. Thus, the results of this study were consistent with the working hypothesis that prolonged CYP1A1/1A2 induction by MC was caused by mechanisms other than those due to persistent retention of carcinogen in liver.
The band shift in MC-treated animals at 24 h but not in control animals (Fig. 11), as detected by EMSA, most probably represented interaction of the MC-AHR-ARNT complex with AhREs of the CYP1A1 promoter. The fact that the band shift was no longer observed in animals 15 days after MC withdrawal suggests that AHR-independent mechanisms significantly contributed to the long-term induction of CYP1A1/1A2 by MC. We have not excluded the possibility that, at later time points, a metabolite of MC or an endogenous ligand activated the AHR, which in turn interacted with some regulatory elements on the CYP1A1 promoter that were not present in the oligo probes that we used in our EMSAs.
The mechanisms of sustained induction of CYP1A enzymes by MC are not understood. It is possible that certain types of chemical stress response(s) associated with PAH treatment may have contributed to the sustained induction after MC exposure. As regards the lack of CYP1A induction after administration of a low dose of MC (2 µmol/kg), it is conceivable that this phenomenon was, in part, due to an inflammatory response. Because it is known that cytokine release is associated with PAH treatment, it is likely that the cytokine-mediated down-regulation of CYP enzymes contributed to the lack of CYP1A induction.
Regardless of the mechanism of persistent induction of CYP1A1/1A2 by
MC, the phenomenon of sustained induction by MC may have significant
implications for carcinogenesis by PAHs. These implications are:
1) because CYP1A1/1A2 are involved in the metabolic activation of PAHs
to DNA-binding metabolites, exposure to a persistent inducer may lead
to increased or decreased genotoxic risk on subsequent exposure to
other genotoxic carcinogen(s). 2) Persistent induction may enhance
metabolism of PAHs, leading to generation through redox cycling of
increasing amounts of reactive oxygen species which may cause oxidative
DNA damage (Ichinose et al., 1997
). 3) As CYP1A enzymes are involved in
estrogen metabolism (Safe, 1995
), long-term induction of CYP may
enhance the production of estrogenic metabolites, some of which are
tumor promoters.
In conclusion, the results of this study strongly suggest that MC
elicits persistent induction of CYP1A1/1A2 by mechanisms other than
persistence of the parent carcinogen and probably involves AHR-independent mechanisms. A recent study (Dey et al., 1999
) suggesting an important role for CYP1A1 in regulating critical life
processes, in addition to its role in carcinogenesis by PAHs, calls for
further in-depth investigations to elucidate the molecular mechanisms
of persistence of MC-inducible CYP1A1/1A2, a phenomenon which
potentially has important implications for carcinogenesis as well as
other important biological processes.
| |
Acknowledgments |
|---|
I thank Dr. P. E. Thomas of Rutgers University for monoclonal antibodies against CYP1A1/1A2, Dr. F. J. Gonzalez of the National Cancer Institute for CYP1A1/1A2 cDNA probe, and Dr. Toshiya Tamura of the Department of Pediatrics, Baylor College of Medicine for GAPDH cDNA probe. I also thank Drs. C. V. Smith, J. W. Eaton, and S. E. Welty of the Department of Pediatrics for helpful discussions. I am grateful to Dr. Kurt Randerath of the Department of Pharmacology for providing laboratory facilities, support, and encouragement during the initial stages of this work.
| |
Footnotes |
|---|
Accepted for publication March 9, 2000.
Received for publication December 13, 1999.
1 This work was supported in part by U.S. Public Health Service (USPHS) Grant ES09132 from the National Institute of Environmental Health Sciences and a grant-in-aid from the American Heart Association (Texas Affiliate) to B. Moorthy and by USPHS Grant CA32157 from the National Cancer Institute to Kurt Randerath.
Send reprint requests to: Dr. Bhagavatula Moorthy, Ph.D., Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. E-mail: bmoorthy{at}neo.bcm.tmc.edu
| |
Abbreviations |
|---|
MC, 3-methylcholanthrene; PAH, polycyclic aromatic hydrocarbon; TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin; BP, benzo[a]pyrene; AHR, Ah receptor; AhRE, Ah response elements; ARNT, Ah receptor nuclear translocator; EROD, ethoxyresorufin O-deethylase; MROD, methoxyresorufin O-demethylase; AHH, aryl hydrocarbon hydroxylase; HRP, horseradish peroxidase; PAGE, polyacrylamide gel electrophoresis; CO, corn oil; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SSC, sodium chloride sodium citrate; DBA, dibenz[ac]anthracene; EMSA, electrophoretic mobility shift assay.
| |
References |
|---|
|
|
|---|
-naphthoflavone and 3-methylcholanthrene as inducers of hepatic cytochrome(s) P-448 and arylhydrocarbon (benzo[a]pyrene) hydroxylase activity.
Mol Pharmacol
13:
259-268
-napthoflavone or 3-methylcholanthrene.
Cell Struct Funct
9:
53-66[Medline].This article has been cited by other articles:
![]() |
S. R. Kondraganti, W. Jiang, A. K. Jaiswal, and B. Moorthy Persistent Induction of Hepatic and Pulmonary Phase II Enzymes by 3-Methylcholanthrene in Rats Toxicol. Sci., April 1, 2008; 102(2): 337 - 344. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Bohonowych and M. S. Denison Persistent Binding of Ligands to the Aryl Hydrocarbon Receptor Toxicol. Sci., July 1, 2007; 98(1): 99 - 109. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. I. Couroucli, Y. W. Liang, W. Jiang, R. Barrios, and B. Moorthy Attenuation of Oxygen-Induced Abnormal Lung Maturation in Rats by Retinoic Acid: Possible Role of Cytochrome P4501A Enzymes J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 946 - 954. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sinha, K. Muthiah, W. Jiang, X. Couroucli, R. Barrios, and B. Moorthy Attenuation of Hyperoxic Lung Injury by the CYP1A Inducer {beta}-Naphthoflavone Toxicol. Sci., September 1, 2005; 87(1): 204 - 212. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Jiang, S. E. Welty, X. I. Couroucli, R. Barrios, S. R. Kondraganti, K. Muthiah, L. Yu, S. E. Avery, and B. Moorthy Disruption of the Ah Receptor Gene Alters the Susceptibility of Mice to Oxygen-Mediated Regulation of Pulmonary and Hepatic Cytochromes P4501A Expression and Exacerbates Hyperoxic Lung Injury J. Pharmacol. Exp. Ther., August 1, 2004; 310(2): 512 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
|